Products intended exclusively for scientific and laboratory research. Not for human consumption.
FREE shipping on orders over $2,000 MXN · Pay with SPEI or Mercado Pago
Égida Peptides
ES/EN
View catalog
Technical guide

Tirzepatide vs semaglutide: dual or simple GLP-1 agonist

Reviewed by the Égida Peptides technical team · Updated August 26, 2026

Tirzepatide and semaglutide are almost always compared side by side. The difference between them, in one line, is how many receptors each one recognizes: semaglutide one, tirzepatide two. Below we compare the two by structure, by what each one does in receptor pharmacology, and by what changes when a batch is verified in the lab. This is research-use-only (RUO) content: it does not cover human use, dosing, protocols or effects.

One receptor versus two

Semaglutide is a modified GLP-1 analog. GLP-1 is a hormone the gut releases when you eat, and its job is to tell the pancreas to produce insulin. Semaglutide imitates that signal, but with two changes in the sequence and an added fatty-acid chain that make it last in the body far longer than the natural hormone. The Novo Nordisk team described the design in Journal of Medicinal Chemistry in 2015 (see Sources). The result: it activates one receptor, the GLP-1 receptor.

Tirzepatide is a synthetic peptide that activates two receptors: the same GLP-1 receptor, plus the receptor for GIP, another gut hormone that works on the same axis. Hence the dual agonist label. The Eli Lilly team described it in Molecular Metabolism in 2018 (see Sources). The idea behind the design: if one molecule can push two levers in parallel, the biological response changes in ways one lever alone cannot produce.

They are not versions of the same molecule. They are two distinct sequences from two distinct labs, with different receptor profiles. Which one fits a given assay design, or what results each produces, is outside the scope of this RUO material.

"Dual" does not mean twice as strong

The fact that a molecule recognizes two receptors does not mean it activates them with the same intensity or produces twice the effect. A pharmacology study published in JCI Insight in 2020 analyzed tirzepatide in detail and found that the molecule behaves more like a version of native GIP at its receptor, and only partially at the GLP-1 receptor (see Sources). In practical terms: the "dual" label counts receptors, not signaling strength.

Semaglutide does not have that receptor-balance question because it only recognizes one. But it does not behave identically to native GLP-1 either: as a fatty-acid-chain analog, it lasts longer and its signaling pattern is its own, distinct from the endogenous molecule.

The useful takeaway for an assay: do not trust the label. Two compounds with the same last name ("GLP-1 agonist," "dual") can give different results because they activate the same receptors in different ways.

This content is technical and informational about the compounds it covers and how their quality is verified. It is not medical guidance, does not describe human use, dosing, protocols, or effects, and does not claim any therapeutic benefit or compare outcomes between compounds. The products are intended exclusively for research and development in a laboratory setting.

Batch verification: same process, different spec sheet

The procedure to verify a batch is the same for both: what changes is the reference the result is compared against. Each molecule has its own molecular weight and sequence, so the Certificate of Analysis for a semaglutide batch and for a tirzepatide batch is read the same way but compared against different references.

Two data points are what matter. Identity is confirmed by weighing the molecule with mass spectrometry: the measured weight has to hit the correct value for that sequence and not for a different one. Semaglutide is around 4,113 Da; tirzepatide around 4,813 Da. Purity is measured by HPLC, which separates what is inside the vial and calculates what percentage of the total corresponds to the compound you ordered. For the detail of how that number is interpreted, what HPLC purity is explains it, and how to read a COA walks through the full document.

Identity and purity are distinct questions and are often confused. A batch can be 99% pure of something that is not what you ordered. That is why the two tests are read together, and why the COA has to match the batch you actually received rather than a generic catalog reference. If you want the detail of tirzepatide on its own before comparing it, what tirzepatide is covers it separately.

Reconstitution: same math, different vial

Both are distributed lyophilized, as a dry powder, because that is the state in which they travel and store best. The concentration math when you reconstitute is the same for both: it depends on the milligrams in the vial and the volume of liquid you add, not on the peptide. The reconstitution calculator handles that conversion. If it is your first time, the step-by-step guide covers the procedure and bacteriostatic vs. sterile water clarifies which liquid applies in each case.

Which one matches your assay

The choice is an experimental-design decision, not a product-quality comparison. If the work looks only at the GLP-1 receptor (characterizing single-lever signaling, comparing response against the native hormone), semaglutide is the best-characterized modified analog. If the design also needs to include the GIP receptor, tirzepatide is where that comes in. If the glucagon receptor is also required, the matching molecule is retatrutide, and the comparison is covered in retatrutide vs tirzepatide. There is no "better": there is one that matches the receptors your protocol contemplates.

What does apply equally to both is the verification standard. Without a per-batch COA showing HPLC purity and mass identity, the vial label is an unsupported claim, regardless of how many receptors the molecule is said to activate. To see both alongside the rest of the catalog, the comparator puts them side by side and research peptides gathers the full category. If you already know which one matches your protocol, you can buy tirzepatide directly from the catalog. Semaglutide is not part of Égida's current catalog.

Sources

Open the calculator
FAQ

Frequently asked questions

The number of receptors each molecule recognizes. Semaglutide is a modified GLP-1 analog that activates a single receptor: GLP-1R. Tirzepatide is a synthetic peptide that activates two: GIPR and GLP-1R. They are two distinct sequences, not versions of the same molecule.

Recognizing more receptors does not equal activating them with the same intensity or producing twice the effect. The pharmacology literature describes tirzepatide as a molecule that behaves more like a version of native GIP at its receptor and only partially at the GLP-1 receptor. In that sense, "potency" is a pharmacology question, not a product-quality comparison.

The procedure is the same, but the reference changes. In both cases identity is confirmed by mass spectrometry and purity by HPLC; the measured molecular weight is simply compared against the theoretical value for each sequence (semaglutide ~4,113 Da, tirzepatide ~4,813 Da).

No. The resulting concentration depends only on the milligrams in the vial and the volume of liquid added, not on which receptors the peptide activates.

Side effects reported in clinical trials of tirzepatide are outside the scope of RUO material, which is distributed as a laboratory reagent and not as a medicine. That information belongs to the approved-drug label and to peer-reviewed clinical literature; an Égida COA covers only the chemical identity and purity of the batch.

Technical questions about a compound or a batch?

Message us by email and we reply within business hours with COA detail, purity verification or any handling question. For orders, add to cart above.

Message by email